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Abstract
Background: Cigarette smoking is a tough addiction to break. Therefore, improved approaches to smoking
cessation are necessary. The electronic-cigarette (e-Cigarette), a battery-powered electronic nicotine delivery device
(ENDD) resembling a cigarette, may help smokers to remain abstinent during their quit attempt or to reduce
cigarette consumption. Efficacy and safety of these devices in long-term smoking cessation and/or smoking
reduction studies have never been investigated.
Methods: In this prospective proof-of-concept study we monitored possible modifications in smoking habits of 40
regular smokers (unwilling to quit) experimenting the ‘Categoria’ e-Cigarette with a focus on smoking reduction
and smoking abstinence. Study participants were invited to attend a total of five study visits: at baseline, week-4,
week-8, week-12 and week-24. Product use, number of cigarettes smoked, and exhaled carbon monoxide (eCO)
levels were measured at each visit. Smoking reduction and abstinence rates were calculated. Adverse events and
product preferences were also reviewed.
Results: Sustained 50% reduction in the number of cig/day at week-24 was shown in 13/40(32.5%) participants;
their median of 25 cigs/day decreasing to 6 cigs/day (p < 0.001). Sustained 80% reduction was shown in 5/40
(12.5%) participants; their median of 30 cigs/day decreasing to 3 cigs/day (p = 0.043). Sustained smoking
abstinence at week-24 was observed in 9/40(22.5%) participants, with 6/9 still using the e-Cigarette by the end of
the study. Combined sustained 50% reduction and smoking abstinence was shown in 22/40 (55%) participants,
with an overall 88% fall in cigs/day. Mouth (20.6%) and throat (32.4%) irritation, and dry cough (32.4%) were
common, but diminished substantially by week-24. Overall, 2 to 3 cartridges/day were used throughout the study.
Participants’ perception and acceptance of the product was good.
Conclusion: The use of e-Cigarette substantially decreased cigarette consumption without causing significant side
effects in smokers not intending to quit (http://ClinicalTrials.gov number NCT01195597).
Background
With well over one billion smokers’ worldwide, cigarette
smoking is a global epidemic that poses a substantial
health burden and costs [1]. This is because cigarette
smoke harms several organ systems of the human body,
thus causing a broad range of diseases, many of which
are fatal [2,3]. The risk of serious disease diminishes
rapidly after quitting and life-long abstinence is known
to reduce the risk of lung cancer, heart disease, strokes,
chronic lung disease and other cancers [4,5].
Although evidence-based recommendations indicate
that smoking cessation programs are useful in helping
smokers to quit [6], smoking is a very difficult addiction
to break. It has been shown that approximately 80% of
smokers who attempt to quit on their own, relapse
within the first month of abstinence and only about 3-
5% remain abstinent at 6 months [7]. Although there is
little doubt that currently-marketed smoking cessation
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stop smoking, they reportedly lack high levels of effi-
cacy, especially in the real life setting [8]. Although this
is known to reflect the chronic relapsing nature of
tobacco dependence, the need for novel and effective
approaches to smoking cessation interventions is beyond
doubt.
The electronic-cigarette (e-Cigarette) is a battery-pow-
ered electronic nicotine delivery device (ENDD) resem-
bling a cigarette designed for the purpose of nicotine
delivery,where no tobacco or combustion is necessary
for its operation [9] (Figure 1). Consequently, this pro-
duct may be considered as a lower risk substitute for
factory-made cigarettes. In addition, people report buy-
ing them to help quit smoking, to reduce cigarette con-
sumption and to relieve tobacco withdrawal symptoms
due to workplace smoking restrictions [10]. Besides deli-
vering nicotine, e-Cigarettes may also provide a coping
mechanism for conditioned smoking cues by replacing
some of the rituals associated with smoking gestures (e.
g. hand-to-mouth action of smoking). For this reason, e-
Cigarettes may help smokers to remain abstinent during
their quit attempt or to reduce cigarette consumption.
A recent internet survey on the satisfaction of e-Cigar-
ette use has reported that the device helped in smoking
abstinence and improved smoking-related symptoms
[11]. Under acute experimental conditions, two mar-
keted electronic cigarette brands suppressed tobacco
abstinence symptom ratings without leading to measur-
able levels of nicotine or CO in the exhaled breath [12].
The e-Cigarette is a very hot topic that has generated
considerable global debate with authorities wanting to
ban it or at least regulate it. Consequently, a formal
demonstration supporting the efficacy and safety of
these devices in smoking cessation and/or smoking
reduction studies would be of utmost importance.
With this in mind, we designed a prospective proof-
of-concept study to monitor possible modifications in
the smoking habits of a group of well characterized reg-
ular smokers experimenting the most popular marketed
e-Cigarette in Italy (’Categoria’; Arbi Group Srl, Milano,
Italy) focusing on smoking reduction and smoking absti-
nence. We also monitored adverse events and measured
participants’ perception and acceptance of the product.
Methods
Participants
Healthy smokers 18-60 years old, smoking ≥ 15 factory-
made cigarettes per day (cig/day) for at least the past 10
years and not currently attempting to quit smoking or
w i s h i n gt od os oi nt h en e x t3 0d a y sw e r er e c r u i t e d
from the local Hospital staff in Catania, Italy. None of
the participants reported a history of alcohol and illicit
drug use, major depression or other psychiatric condi-
tions. We also excluded subjects who reported recent
myocardial infarction, angina pectoris, high blood pres-
sure (BP > 140 mmHg systolic and/or 90 mmHg diasto-
lic), diabetes mellitus, severe allergies, poorly controlled
asthma or other airways diseases. The study protocol
was discussed with the Chair of the local institutional
ERB (Comitato Etico Azienda Vittorio Emanuele) in
February 2010. In consideration of the fact that e-cigar-
ette use is a widespread phenomenon in Italy, that many
e-cigarette users are enjoying them as consumer goods,
that this type of product is not regulated as a drug or a
drug device in Italy (end users can buy e-cig almost
Figure 1 Structure of the ‘Categoria’ electronic-cigarette (e-Cigarette). The e-Cigarette is a battery-powered electronic nicotine delivery
device (ENDD) resembling a cigarette designed for the purpose of providing inhaled doses of nicotine by way of a vaporized solution to the
respiratory system. This device provides a flavor and physical sensation similar to that of inhaled tobacco smoke, while no smoke or combustion
is actually involved in its operation. It is composed of the following key components: (1) the inhaler - also known as ‘cartridge’ (a disposable
non-refillable plastic mouthpiece - resembling a tobacco cigarette’s filter - which contains an absorbent material that is saturated with a liquid
solution containing nicotine); (2) the atomizing device (the heating element that vaporizes the liquid in the mouthpiece and generates the mist
with each puff); (3) the battery component (the body of the device - resembling a tobacco cigarette - which houses a lithium-ion re-chargeable
battery to power the atomizer). The body of the device also houses an electronic airflow sensor to automatically activate the heating element
upon inhalation and to light up a red LED indicator to signal activation of the device with each puff. Each pre-filled ‘Original’ cartridges used in
this study contains nicotine (7.25 mg/cartridge) dissolved in propylene glycol (233.7 mg/cartridge) and vegetable glycerin (64.0 mg/cartridge)
[details can be found at: http://www.liaf-onlus.org/public/allegati/categoria1b.pdf].
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rants, and shops), and that only healthy smokers not
willing to quit smoking would participate, it was felt
that the study fulfilled the criteria of an observational
naturalistic investigation and was exempt from the
requirement from ethical approval. Participants gave
written informed consent prior to participation in the
study.
Study Design and Baseline Measures
Eligible participants were invited to use an ENDD
(’Categoria’ e-Cigarette, Arbi Group Srl, Milano, Italy)
and were followed up prospectively for 6 months. They
attended a total of five study visits at our smoking cessa-
tion clinic (Centro per la Prevenzione e Cura del Taba-
gismo (CPCT), Università di Catania, Italy): a baseline
visit and four follow-up visits, (at week-4, week-8, week-
12 and week-24) (Figure 2).
At baseline (study visit 1), basic demographic and a
detailed smoking history were taken and individual
pack-years (pack/yrs) calculated together with scoring of
their level of nicotine dependence by means of Fager-
strom Test of Nicotine Dependence (FTND) question-
naire [13]. Subjective ratings of depression were assessed
with the Beck Depression Inventory (BDI) [14]. Addi-
tionally, levels of carbon monoxide in exhaled breath
(eCO) were measured using a portable device (Micro
CO, Micro Medical Ltd, UK). Participants were given a
free e-Cigarette kit containing two rechargeable bat-
teries, a charger, and two atomizers and instructed on
how to charge, activate and use the e-Cigarette. Key
troubleshooting were addressed and phone numbers
were supplied for both technical and medical assistance.
A full 4-weeks supply of 7.4 mg nicotine cartridges
("Original” cartridges; Arbi Group Srl, Milano, Italy) was
also provided and participants were trained on how to
load them onto the e-Cigarette’s atomizer. Random
checks confirmed that the nicotine content per cartridge
was 7,25 mg. Detailed toxicology and nicotine content
analyses of “Original” cartridges had been carried in a
laboratory certified by the Italian Institute of Health and
can be found at: http://www.liaf-onlus.org/public/alle-
gati/categoria1b.pdf
Participants were permitted to use the study product
ad libitum throughout the day (up to a maximum of 4
cartridges per day, as recommended by the manufac-
turer) in the anticipation of reducing the number of cig/
day smoked, and to fill a 4-weeks’ study diary recording
product use, number of any tobacco cigarettes smoked,
and adverse events.
Participants were invited to came back at week-4
(study visit 2), week-8 (study visit 3), and week-12 (visit
4), a) to receive further free supply of nicotine cartridges
together with the study diaries for the residual study
periods, b) to record their eCO levels, and c) to give
back completed study diaries and unused study
products.
Study participants attended a final follow-up visit at
week-24 (study visit 5) to report product use (car-
tridges/day) and the number of any tobacco cigarettes
smoked (from which smoking reduction and smoking
abstinence could be calculated), to re-check eCO
levels and to rate the degree of usefulness of the
study product. In particular, participants were asked
to rate their level of satisfaction with the products
compared to their usual cigarettes using a visual ana-
l o g u es c a l e( V A S )f r o m0t o1 0p o i n t s( 0=b e i n g
‘completely unsatisfied’,1 0b e i n g=‘fully satisfied’);
on the same scale, they also rated helpfulness (in
k e e p i n gt h e mf r o ms m o k i n g )a n dw h e t h e rt h e yw o u l d
recommend it to a friend who wanted to stop/reduce
smoking. Adverse events were obtained from their
study diaries.
Given the observational nature of this study, no
emphasis on encouragement, motivation and reward for
the smoking cessation effort were provided since this
study was intended to monitor the case of a smoker
(unwilling to quit) trying out an unconventional nicotine
delivery device in a real world setting. Although partici-
pants were allowed to smoke their own brand of cigar-
ette as they wished, smoking cessation services were
provided to those who would spontaneously ask for
assistance with quitting. These subjects were excluded
from the study protocol.
Study outcome measures
The primary efficacy measure was sustained 50% reduc-
tion in the number of cig/day at week-24 from baseline
(reducers) [15]; defined as sustained self-reported 50%
reduction in the number of cig/day compared to base-
line for the 30 days period prior to week-24 study visit
(eCO levels were measured to verify smoking status and
confirm a reduction compared to baseline).
A secondary efficacy measure of the study was sus-
tained 80% reduction in the number of cig/day at week-
24 from baseline (heavy reducers); defined as sustained
self-reported 80% reduction in the number of cig/day
compared to baseline for the 30 days period prior to
week-24 study visit (eCO levels were measured to verify
smoking status and confirm a reduction compared to
baseline).
An additional secondary efficacy measure of the study
was sustained smoking abstinence at week-24 (quitters);
defined as complete self-reported abstinence from
tobacco smoking (not even a puff) for the 30 days per-
iod prior to week-24 study visit (eCO levels were mea-
sured to objectively verify smoking status with an eCO
concentration of ≤10 ppm).
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Page 3 of 1266 subjects (38M; 28F)
responded to the study advert
52 subjects (29 M; 23 F)
consented to participate
40 subjects (26 M; 14F) eligible for inclusion in the study
and assigned to use the e-Cigarette
27 subjects (18M;9F) eligible for week-24 analyses
30 subjects (21M;9F) eligible for week-12 analyses
32 subjects (22M;10F) eligible for week-8 analyses
34 subjects (23M;11F) eligible for week-4 analyses
14 subjects (9M; 5F) ineligible due to
their request to be assisted with quitting
12 subjects (3M; 9F) ineligible due to
exclusion criteria (6 hypertension; 2 age > 60 yrs;
2 Hx of major depression; 1 Hx of recent
myocardial infarction;  1 Hx of asthma)
6 subjects (4M; 2F):
lost to follow up
2 subjects (1M; 1F):
lost to follow up
2 subjects (1M; 1F):
lost to follow up
3 subjects (3M):
lost to follow up
Baseline Visit 1
Visit 2
Visit 3
Visit 4
Final Visit 5
Figure 2 Number of patients recruited and flow of patients within the study. A total of 66 subjects with specifically predefined smoking
criteria (smoking ≥ 15 cig/day for at least the past 10 years) responded to the advert; of these, 14 subjects were not included in the study
because they spontaneously seek assistance with quitting (these were then invited to attend the local smoking cessation clinic, which offers
standard support with cessation counselling and pharmacotherapy for nicotine dependence). The remaining 52 subjects consented to participate
into the study; of these, 12 were not considered eligible because of the exclusion criteria (6 had a high blood pressure, 2 were older than 60; 2
had a diagnosis of major depression; 1 suffered from recent myocardial infarction; 1 had uncontrolled allergic asthma). In the end, 40 volunteers
were included in the study and were issued with e-Cigarette kits loaded with nicotine cartridges. By the end of the study, a total of 13 subjects
were lost to follow-up due to failure of attending their control visits. Overall 27 participants were available for analyses at the 24-week follow-up
visit.
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at the final week-24 follow-up visit (study visit 5) were
categorized as reduction/cessation failures (failures).
Statistical Analyses
This was a proof-of-concept pilot study, the first of its
kind, hence no previous data could be used for power
calculation. However, using our previous experience in
smoking cessation studies, we estimated that a sample
of 40 subjects would have been adequate to acquire
quit/reduction rates from 70-75% of the subjects
enrolled [16]. Primary and secondary outcome measures
were computed by including all enrolled participants -
assuming that all those individuals who were lost to fol-
low-up are classified as failures (intention-to-treat analy-
sis). The changes from baseline (study visit 1) in
number of cig/day and in eCO levels were compared
with data recorded at subsequent follow-up visits using
Wilcoxon Signed rank test as these data were non-para-
metric. Parametric and non-parametric data were
expressed as mean (± SD) and median (interquartile
range (IQR)) respectively. Correlations were calculated
using Spearman’s Rho Correlation. Statistical methods
were 2-tailed, and P values of < 0.05 were considered
significant.
Results
Participant characteristics
After excluding for the study exclusion criteria, a total
of 40 (M 26; F 14; mean (± SD) age of 42.9 (± 8.8)
years) regular smokers (mean (± SD) pack/yrs of 34.9
(± 14.7)) consented to participate and were included
in the study (Table 1; Figure 2). Twenty-seven (67.5%)
completed all study visits and returned for their final
follow-up visit at week-24. Baseline characteristics of
those who were lost to follow-up were not signifi-
cantly different from participants who completed the
study.
Outcome measures
Participants’ smoking status at baseline and at 24-week
is shown on Table 2. Taking the whole cohort of partici-
pants (n = 40), an overall 80% reduction in median cig/
day use from 25 to 5 was observed by the end of the
study (p < 0.001). Sustained 50% reduction in the num-
ber of cig/day at week-24 was shown in 13/40 (32.5%)
participants, with a median of 25 cig/day (IQR 20, 30)
decreasing significantlyt o6c i g / d a y( I Q R5 ,6 ) ( p<
0.001). Of these tobacco smoke reducers, five (12.5%)
could be classified as sustained heavy reducers (at least
80% reduction in the number of cig/day) at week-24.
They had a median consumption of 30 cig/day (IQR 25,
35) at baseline, decreasing significantly to 3 cig/day
(IQR 3, 6) (p = 0.043). There were 9/40 (22.5%) quitters,
with 6/9 still using the e-Cigarette by the end of the
study. Overall, combined sustained 50% reduction and
smoking abstinence was shown in 22/40 (55%) partici-
pants, with a median of 25 cig/day (IQR 20, 30) decreas-
ing significantly to 3 cig/day (IQR 0, 6)(p < 0.001),
which is equivalent to an overall 88% reduction. Details
of mean cigarette use and eCO levels throughout the
study is shown in Figure 3 and 4.
Table 1 Patient Demographics
Parameter Mean (± SD)*
Subjects eligible for inclusion(n = 40)
Age 42.9 (± 8.8)
Sex 26M; 14F
Smoking Years 26.9 (± 8.8)
FTND 6.0 (6, 8)*
Beck Depression Inventory 9 (5, 12.3)*
Cigarettes/day 25 (20, 30)*
eCO 23.5 (15.8, 36)*
†Subjects available for week-24 analyses(n = 27)
Age 42.6 (± 8.4)
Sex 18M; 9F
Smoking Years 27.2 (± 8.9)
FTND 7 (6, 7)*
Beck Depression Inventory 9 (5, 12.5)*
Cigarettes/day 25 (20, 30)*
eCO 24 (15.5, 37)*
*Non-parametric data expressed as median (IQR).
† Subjects excluding those lost-to-follow-up.
Abbreviations: SD - Standard Deviation; M - Male; F - Female; FTND - Fagerstrom Test of Nicotine Dependence; eCO - exhaled carbon monoxide; IQR -
interquartile range.
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Details of mean cartridge use throughout the study is
shown in Figure 5. The reported number of cartridges/
d a yu s e db yo u rs t u d yp a r t i c i p a n t sw a sd i s s i m i l a r ,r a n -
ging from a maximum of 4 cartridges/day (as per manu-
facturer’s recommendation) to a minimum of 0
cartridges/day (’zero’ was recorded in the study diary,
when the same cartridge was used for more than 24
hours). For the whole group (n = 27), a mean (± SD)
2.0 (± 1.4) cartridges/day was used throughout the
study. The number of cartridges/day used was slightly
higher when these summary statistics were computed
with the exclusion of the eight study failures; the value
increasing to a mean (± SD) of 2.2 (± 1.3) cartridges/
day. Correlation between the number of cartridges/day
and smoking reduction in those participants with
sustained 50% reduction in smoking was not significant
(Rho -0.003; p = 0.988). Likewise, the correlation
between the number of cartridges/day, and combined
sustained 50% reduction and smoking abstinence was
also non-significant (Rho -0.185; p = 0.546).
Adverse Events
The most frequently reported adverse events were
mouth irritation (20,6%), throat irritation (32,4%), and
dry cough (32,4%) (Table 3). These events were most
commonly reported at the beginning of the study and
appeared to wane spontaneously by study visit 5.
Remarkably, side effects commonly recorded during
smoking cessation trials with drugs for nicotine depen-
dence were absent (i.e. depression, anxiety, insomnia,
irritability, hunger, constipation were not reported).
Table 2 Subject Parameter Outcomes Following 24 Weeks of Electronic Cigarette Use
Parameter AT BASELINE AT 24-Weeks
Post E-Cigarette
p value‡
Sustained 50% (excluding quitters) reduction in cigarette smoking (n = 13)
Age 40.1 (± 7.7)† 6 (5, 6)* < 0.001
Sex 8M; 5F 8 (6, 11)* 0.001
Smoking Years 24.5 (± 8.7)†
Cigarettes/day 25 (20, 30)*
eCO 18 (14, 33)*
Sustained 80% (excluding quitters) reduction in cigarette smoking (n = 5)
Age 40.6 (± 10.4)† 3 (3, 6)* 0.043
Sex 4M; 1F 6 (4, 10)* 0.042
Smoking Years 25.4 (± 11.8)†
Cigarettes/day 30(25, 35)*
eCO 15 (14, 44)*
Sustained 100% (quitters) reduction in cigarette smoking (n = 9)
Age 44.7 (± 9.3)† 0 (0, 0)* 0.008
Sex 8M; 1F 3 (2, 3)* 0.008
Smoking Years 29 (± 9.6)†
Cigarettes/day 25 (23, 30)*
eCO 31 (23, 41)*
Sustained > 50% (including quitters) reduction in cigarette smoking (n = 22)
Age 42 (± 8.5)† 3 (0, 6)* < 0.001
Sex 16M; 6F 5.5 (3, 9.5)* < 0.001
Smoking Years 26.3 (± 9.1)†
Cigarettes/day 25 (20, 30)*
eCO 27 (15.5, 37.5)*
Smoking Failure (< 50% smoking reduction) (n = 5)
Age 45.6 (± 7.9)† 20 (20, 20)* 0.157
Sex 2M; 3F 28 (17, 31)* 0.892
Smoking Years 31.2 (± 7)†
Cigarettes/day 25 (20, 25)*
eCO 18 (16, 32)*
Abbreviations: SD - Standard Deviation; M - Male; F - Female; eCO - exhaled carbon monoxide.
‡p value - within group Wilcoxon Signed Rank Test.
† Parametric data expressed as mean (± SD).
*Non-parametric data expressed as median (interquartile range(IQR)).
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ing unscheduled visit to the family practitioner or hospi-
talisation) occurred during the study.
Product Preferences
The ‘Categoria’ e-Cigarette rated scores well above the
mean for satisfaction and for helpfulness (enabling them
to refrain from smoking), their mean (± SD) VAS values
being 6.3 (± 2.5) and 7.5 (± 2.7) respectively. Moreover,
i tw a so b s e r v e dt h a tp a r t i c i p a nts would enthusiastically
recommend the e-Cigarette to friends or relatives who
wanted to stop/reduce smoking, the mean (± SD) VAS
value being 8.0 (± 3.4). Predictably, the e-Cigarette rated
even higher scores when these summary statistics were
computed with the exclusion of the study failures (n =
8). On the contrary, the perception and acceptance of
the product by those who failed to remain abstinent or
to reduce smoking (n = 5) was poor; the mean (± SD)
VAS values for satisfaction and for helpfulness being 2.2
(± 0.8) and 2.5 (± 1.0), respectively. As expected, these
individuals were unlikely to recommend the ‘Categoria’
e-Cigarette to friends or relatives; the mean (± SD) VAS
value being 2.3 (± 1.2).
Among the most positive features of e-Cigarettes were
the pleasure of inhalation and exhalation of the vapour.
Other positive features mentioned included cleaner and
fresher breath, absence of odours in clothing and hair.
Although the overall participants’ perception and accep-
tance of the product was good, its ease of use could be
improved and technical defects reduced. During the
course of the study, five study participants could not use
the product as recommended and had to be retrained
-5
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Page 7 of 12within 72 hours. Three participants reported that the
device often failed to produce mist when puffed (three
atomizers had to be substituted). Another two were
given a faulty charger (chargers were immediately
replaced). According to study participants, perception
and acceptance of the product could be improved by
increasing manufacturing standards, by providing a
recharge lasting at least 24 hours, by reducing the
weight of the device and by substituting the hard plastic
mouthpiece.
Discussion
In this pilot study, we have shown for the first time that
substantial and objective modifications in the smoking
habits may occur in smokers using e-Cigarettes, with
significant smoking reduction and smoking abstinence
and no apparent increase in withdrawal symptoms. Par-
ticipants were not only enthusiastic about using the e-
Cigarette, but the majority (67.5%) were also able to
adhere to the program and to return for the final fol-
low-up visit at week-24 with an overall quit rate of
22.5%. Moreover, at least 50% reduction in cigarette
smoking was observed in 32.5% of participants. Overall,
combined reduction and smoking abstinence was shown
in 55% of participants. These preliminary findings are of
great significance in view of the fact that all smokers in
the study were, by inclusion criteria, not interested in
quitting. Although not directly comparable with classic
cessation and/or reduction studies with other pharma-
ceutical products because of its design (the present
study is not an ordinary cessation study), the results of
our study are in general accordance with the findings
published in the medical literature [17].
The large magnitude of this effect suggests the e-
Cigarette strongly suppressed cigarette use. However, no
correlations were observed between the number of
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Page 8 of 12nicotine cartridges/day used and the level of smoking
reduction. This is not unexpected, in view of the power-
ful interaction between physical and behavioural depen-
dence of smoking [18,19] and the modest increases in
blood nicotine levels measured after the use of this type
of devices [20]. Therefore, it is unlikely that the
observed positive effect of the e-Cigarette is due to nico-
tine delivery. Rather, the strong suppression of smoking
in association with the absence of correlation between
cartridges use and level of smoking reduction, suggests
that the positive effect of the e-Cigarette may be also
due to its capacity to provide a coping mechanism for
conditioned smoking cues by replacing some of the
rituals associated with smoking gestures (e.g. hand-to-
mouth action of smoking). In agreement with this, we
have recently demonstrated that nicotine free inhalators
can only improve quit rates in those smokers for whom
handling and manipulation of their cigarette played an
important role in their ritual of smoking [21].
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Table 3 Adverse events reported by participants who
completed all study visits
Adverse Event Study Visits
4-week
n/n (%)
8-week
n/n (%)
12-week
n/n (%)
24-week
n/n (%)
Throat
irritation*
11/34
(32,4%)
5/32
(15,6%)
5/30
(16,7%)
4/27
(14,8%)
Mouth
Irritation*
7/34 (20,6%) 4/32
(12,5%)
3/30
(10,0%)
2/27 (7,4%)
Sore Throat 4/34 (11,8%) 1/32 (3,1%) 1/30 (3,3%) 0/27 (0,0%)
Dry cough 11/34
(32,4%)
6/32
(18,8%)
3/30
(10,0%)
3/27
(11,1%)
Dry mouth 3/34 (8,8%) 1/32 (3,1%) 1/30 (3,3%) 1/27 (3,7%)
Mouth ulcers 1/34 (2,9%) 1/32 (3,1%) 1/30 (3,3%) 0/27 (0,0%)
Dizziness
§ 5/34 (14,7%) 2/32 (6,3%) 2/30 (6,7%) 1/27 (3,7%)
Headache 4/34 (11,8%) 2/32 (6,3%) 2/30 (6,7%) 1/27 (3,7%)
Nausea 5/34 (14,7%) 2/32 (6,3%) 1/30 (3,3%) 1/27 (3,7%)
* Throat and mouth irritation were described either as tickling, itching, or
burning sensation
§ Dizziness, was also used to mean vertigo and light-headedness.
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ciated with withdrawal effects, typical withdrawal symp-
toms of smoking cessation trials with drugs for nicotine
dependence were not reported during the course of the
study. It is possible that the e-Cigarette by providing a
coping mechanism for conditioned smoking cues could
mitigate withdrawal symptoms associated with smoking
reduction and smoking abstinence. In contrast from
other ENDDs such as Eclipse (which is known to gener-
ate substantial level of eCO) [22], e-Cigarettes use does
not lead to increased eCO levels [12]. In the present
study, the smoking reduction with ‘Categoria’ e-Cigar-
ette use was associated to a substantial decrease in the
level of eCO. The most frequent adverse events were
mouth irritation, throat irritation and dry cough, but all
appeared to wane spontaneously with time. These are
likely to be secondary to exposure to propylene glycol
mist generated by the e-Cigarette’s atomizer. Propylene
glycol is a low toxicity compound widely used as a food
additive and in pharmaceutical preparations. Exposure
to propylene glycol mist may occur from smoke genera-
tors in discotheques, theatres, and aviation emergency
training and is known to cause ocular, mouth, throat,
upper airway irritation and cough [23,24]. Dizziness was
often reported by participants at the beginning of the
study and can be brought about by the hyperventilation
associated to the greater puffing time with the e-Cigar-
ette. Alternatively, the dizziness as well as other
reported adverse events such as nausea and headaches
may be due to nicotine overuse. The substantial reduc-
tion in the frequency of dizziness observed by the end
of the study may be due to the improved familiarisation
with the puffing technique and/or to the overall reduc-
tion in nicotine use. Therefore, the ‘Categoria’” e-Cigar-
ette can be seen as a safe way to smoke although larger
and longer studies will be required for a full assessment
of its adverse events.
The ‘Categoria’ e-Cigarette rated high scores for a
range of subjective ratings of user preferences suggesting
that the product was functioning as an adequate cigar-
ette substitute. Hence, participants were more likely to
recommend the e-Cigarette to friends or relatives. Con-
versely, as would be expected the perception and accep-
t a n c eo ft h ep r o d u c tb yt h o s ew h of a i l e dt or e m a i n
abstinent or to reduce smoking was poor and these indi-
viduals were unlikely to recommend the e-Cigarette. We
cannot exclude that technical problems (particularly
those who went unreported) and difficulty of use (it
takes time to familiarize with the puffing technique)
could have affected the number of lost to follow-up and
failures. Although the overall participants’ perception
and acceptance of the product was good, its ease of use
could be improved. Technical defects could be reduced
by increasing manufacturing standards, providing a
recharge lasting at least 24 hours, reducing the weight
of the device and substituting the hard plastic mouth-
piece. These latter two suggestions would improve
device acceptability for certain common rituals of cigar-
ette smoking, e.g. keeping the cigarette between lips.
Harm-reduction strategies are aimed at reducing the
adverse health effects of tobacco use in individuals
unable or unwilling to quit. Reducing the number of
cig/day is one of several kinds of harm reduction strate-
gies [25]. It is uncertain whether substantial smoking
reduction in smokers using the e-Cigarette will translate
in health benefits, but a number of studies have ana-
lyzed the ability of smoking reduction to lower health
risks and have reported some reductions in cardiovascu-
lar risk factors and lung cancer mortality [26-28]. More-
over, reduction in cigarette smoking by e-Cigarette may
well increase motivation to quit as indicated by a sub-
stantial body of evidence showing that gradually cutting
down smoking can increase subsequent smoking cessa-
tion among smokers [15,29-32]. While not the treatment
of choice, reduced smoking strategies might be consid-
ered for recalcitrant smokers unwilling to quit, as in the
case of our study population.
There are some limitations in our study. Firstly, this
was a small uncontrolled study, hence the results
observed may be due to a chance finding and not to a
true effect; consequently the results should be inter-
preted with caution. However, it would have been quite
problematic to have a placebo arm in such a study. Sec-
ondly, 32.5% of the participants failed to attend their
f i n a lf o l l o w - u pv i s i t ,b u tt h i si sn o tu n e x p e c t e di na
smoking cessation study. Thirdly, because of its unusual
design (smokers not willing to quit, e-Cigarettes were
used throughout the entire study period) this is not an
ordinary cessation study and therefore direct compari-
son with other smoking cessation products cannot be
made. Fourthly, failure to complete the study and smok-
ing cessation failures could be due to occurrence of
technical defects for the e-Cigarette. However, this
could not be assessed with confidence in the present
study. Lastly, assessment of withdrawal symptoms in our
study was not rigorous. Withdrawal was assessed at
each visit by simply asking about the presence/absence
of irritability, restlessness, difficulty concentrating,
increased appetite/weight gain, depression or insomnia.
It is likely that this way of collecting information is
liable to recall bias. Therefore, the reported lack of with-
drawal symptoms in the study participants should be
considered with caution.
Conclusions
Current smoking cessation interventions can increase
t h ec h a n c eo fq u i t t i n gi nc o m m i t t e ds m o k e r sw h oa r e
already motivated and prepared to stop smoking [33],
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to bring more smokers into treatment and increase the
numbers who are motivated to make quit attempts.
Although not formally regulated as a pharmaceutical
product, the e-Cigarette can help smokers to remain
abstinent or reduce their cigarette consumption. By
replacing tobacco cigarettes, the e-cigarette can only
save lives.
Here we show for the first time that e-Cigarettes can
substantially decrease cigarette consumption without
causing significant side effects in smokers not intending
to quit. However, large and carefully conducted RCTs
will be required before a definite answer about the effi-
cacy and safety of these devices can be formulated.
Some of these trials are now in progress in Italy [34-36]
and New Zealand [37] and hopefully they will be able to
confirm and expand the preliminary observations
reported in the present article.
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